Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

It is estimated that drug-resistant infections could cause 10 million deaths each year by 2050 and an annual economic cost of £69 trillion. Three major initiatives in MPLS are working to tackle the problems of antimicrobial resistance (AMR).

Antimicrobial resistance

The Ineos Oxford Institute for Antimicrobial Research (IOI) is a new biomedical discovery institute established to lead the science, provide the evidence, and educate the public in ways that support global transformational change to tackle antimicrobial resistance. Visit the Ineos Oxford Institute website for more information.

'Beyond Antibiotics' is a major new collaborative programme that started in October 2021, funded by the EPSRC and led by Professor Eleanor Stride. The primary focus is the development of new technology to enable: better characterisation of bacterial infections, rapid point-of-care diagnostics, high-throughput testing of new therapies, alternatives to antibiotics and infection prevention strategies. Read more about 'Beyond Antibiotics'.

Led by Professor Craig MacLean in the Department of Biology, the Oxford AMR Network harnesses the University of Oxford’s expertise to tackle the global health challenge. To find out more or join the network, please visit Ineos Oxford Institute.